Rain Oncology Inc. Common Stock
RAIN
RAIN was delisted on the 25th of January, 2024.
57 hedge funds and large institutions have $13.9M invested in Rain Oncology Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 15 closing their positions.
8% less funds holding
Funds holding: 62 → 57 (-5)
18.45% less ownership
Funds ownership: 62.87% → 44.42% (-18%)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
30% less capital invested
Capital invested by funds: $20M → $13.9M (-$6.08M)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
+$448K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$434K |
| 3 |
Two Sigma Advisers
New York
|
+$105K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$92.2K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$61.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$721K |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$417K |
| 3 |
Goldman Sachs
New York
|
-$230K |
| 4 |
Jane Street
New York
|
-$109K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$84.1K |
RAIN Hedge Fund Activity: Q3 2023 in Review
57 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q3 2023, worth a combined $13.9M — down 30% from $20M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RAIN and 10 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Acuitas Investments, opening a new position worth an estimated $448K. The largest seller was Millennium Management, exiting entirely with an estimated $721K sold.
- 57 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q3 2023, down from 62 in Q2 2023.
- Funds reported $13.9M of Rain Oncology Inc. Common Stock stock for Q3 2023, down 30% quarter-over-quarter.
- 10 funds opened new Rain Oncology Inc. Common Stock positions in Q3 2023 and 15 closed out, a net change of -5 holders.
- The largest Rain Oncology Inc. Common Stock buyer in Q3 2023 was Acuitas Investments, an estimated $448K added.
- The largest Rain Oncology Inc. Common Stock seller in Q3 2023 was Millennium Management, an estimated $721K sold.
Based on aggregated 13F filings for Q3 2023.